Dopaminergic agonists that result in ocular growth inhibition also elicit transient increases in choroidal thickness in chicks.
The dopaminergic system has been implicated in ocular growth regulation in chicks and monkeys. In both, dopamine D2 agonists inhibit the development of myopia in response to form deprivation, and in chicks, to negative lenses as well. Because there is mounting evidence that the choroidal response to defocus plays a role in ocular growth regulation, we asked whether the effective agonists also elicit transient thickening of the choroid concomitant with the growth inhibition. Negative lenses mounted on velcro rings were worn on one eye starting at age 8-12 days. Intravitreal injections (20 μl; dose = 10 nmole) of the agonist (dissolved in saline) or saline, were given through the superior temporal sclera using a 30G needle. Eyes were injected daily at noon, for 4 days, and the lenses immediately replaced. Agonists used were apomorphine (non-specific; n = 17), quinpirole (D2; n = 10), SKF-38393 (D1; n = 9), and saline controls (n = 22). For the antagonists, the same protocol was used, but on each day, the lenses were removed for 2 h. Immediately prior to lens-removal, the antagonist was injected (20 μl; dose = 5 nmole). Antagonists used were methylergonovine (non-specific; n = 12), spiperone (D2; n = 20), SCH-23390 (D1; n = 6) and saline controls (n = 27). Comparisons to saline (continuous lens wear) controls were from the agonist experiment. Axial dimensions were measured using high frequency A-scan ultrasonography at the start of lens wear, and on day 4 prior to the injections, and then again 3 h later. Refractive errors were measured using a Hartinger's refractometer at the end of the experiment. Apomorphine and quinpirole inhibited the refractive response to the hyperopic defocus induced by the negative lenses (drug vs saline controls: -1.3 and 1.2 D vs -5.6 D; p < 0.005 for both). This effect was axial: both drugs prevented the excessive ocular elongation (change in axial length: 233 and 205 μm vs 417 μm; p < 0.01 for both). Both drugs were also associated with a transient thickening of the choroid over 3 h (41 and 32 μm vs -1 μm; p < 0.01; p = 0.059 respectively) that did not summate: choroids thinned significantly over the 4 day period in all lens-wearing eyes. Two daily hours of unrestricted vision during negative lens wear normally prevents the development of myopia. Spiperone and SCH-23390 inhibited the ameliorating effects of periods of vision on lens-induced refractive error (-2.9 and -2.8 D vs 0.6 D; p < 0.0001), however, the effects on neither axial length nor choroidal thickness were significant. These data support a role for both D1 and D2 receptors in the ocular growth responses.
Nickla
Debora L
DL
The New England College of Optometry, Dept. of Biosciences, 424 Beacon St., Boston, MA 02115, USA. nicklad@neco.edu
Totonelly
Kristen
K
Dhillon
Balprit
B
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D001058:Apomorphine / Q000494:pharmacology; D002645:Chickens; D002829:Choroid / Q000187:drug effects* / Q000473:pathology; D018491:Dopamine Agonists / Q000494:pharmacology*; D018492:Dopamine Antagonists / Q000494:pharmacology; D005123:Eye / Q000254:growth & development* / Q000378:metabolism; D005139:Eyeglasses; D006984:Hypertrophy; D007267:Injections; D009216:Myopia / Q000517:prevention & control*; D019257:Quinpirole / Q000494:pharmacology; D017447:Receptors, Dopamine D1 / Q000819:agonists; D017448:Receptors, Dopamine D2 / Q000819:agonists; D012029:Refraction, Ocular / Q000187:drug effects*; D014822:Vitreous Body
D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D019257:Quinpirole; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D001058:Apomorphine
Optom Vis Sci. 2010 Jan;87(1):53-60
19901858
Nature. 1978 Aug 3;274(5670):513-4
672981
Prog Retin Eye Res. 2010 Mar;29(2):144-68
20044062
Graefes Arch Clin Exp Ophthalmol. 2006 Oct;244(10):1329-35
16550409
Invest Ophthalmol Vis Sci. 1991 Apr;32(5):1674-7
2016144
Vis Neurosci. 1991 Nov;7(5):451-8
1764415
Exp Eye Res. 2007 Jan;84(1):100-7
17094962
Eur J Neurosci. 1996 Nov;8(11):2286-97
8950093
Neuropharmacology. 2003 Jun;44(8):1038-46
12763097
Optom Vis Sci. 2004 Feb;81(2):111-8
15127930
Curr Eye Res. 1997 Feb;16(2):152-7
9068946
Proc Natl Acad Sci U S A. 1989 Jan;86(2):704-6
2911600
Vis Neurosci. 1997 Mar-Apr;14(2):351-6
9147486
Ciba Found Symp. 1990;155:45-57; discussion 57-62
2088680
J Comp Neurol. 1978 Jul 15;180(2):203-20
207745
Neuropharmacology. 1977 Sep;16(9):549-56
21357
Exp Eye Res. 2007 May;84(5):951-9
17395180
Invest Ophthalmol. 1971 Jun;10(6):438-52
4325307
Vis Neurosci. 1993 May-Jun;10(3):447-53
8494798
Exp Eye Res. 2009 Jun;88(6):1092-9
19450449
Vis Neurosci. 1994 Mar-Apr;11(2):199-208
8003448
Trends Pharmacol Sci. 1994 Jul;15(7):264-70
7940991
Vision Res. 1994 Jan;34(2):143-9
8116274
Eur J Neurosci. 1997 May;9(5):1096-100
9182963
Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5247-53
20445123
Invest Ophthalmol Vis Sci. 2001 Mar;42(3):575-83
11222513
Vision Res. 1987;27(7):1139-63
3660666
Eur J Neurosci. 2005 Apr;21(8):2199-208
15869516
Curr Eye Res. 2006 Jan;31(1):91-105
16421023
Neuroscience. 1998 Apr;83(3):781-9
9483561
Exp Eye Res. 1998 Feb;66(2):163-81
9533843
Doc Ophthalmol. 2004 Jan;108(1):17-40
15104164
Vision Res. 1997 Mar;37(6):659-68
9156210
Vision Res. 1995 May;35(9):1247-64
7610585
Curr Eye Res. 1995 May;14(5):385-9
7648864
Cell Mol Neurobiol. 1990 Sep;10(3):303-25
2174740
Vision Res. 1995 May;35(9):1175-94
7610579
Brain Res. 1995 Oct 16;695(2):110-6
8556320
Optom Vis Sci. 2004 Feb;81(2):137-47
15127933
Ophthalmology. 2008 Aug;115(8):1279-85
18294691